Short-acting beta-agonists (bronchodilators) are the drugs used to treat respiratory diseases, mostly used for treating asthma. Short-acting beta-agonists are known as a quick-acting and relieving medication from asthma attacks, as it helps to rapidly open the airways.
It also provides instant relief to manage both acute and stable exacerbations of chronic obstructive pulmonary disease. The most commonly prescribed drug is salbutamol in the short-acting beta-agonists market.
The short-acting beta-agonists market is likely to grow with the increasing number of patients suffering from asthma and chronic obstructive pulmonary disease.
Pandemic coronavirus is disrupting all the industries. The novel coronavirus is developing various opportunities in the short-acting beta-agonists market. People having any kind of pulmonary disorders are more likely to get coronavirus disease.
Since a huge number of population is suffering from asthma and chronic obstructive pulmonary disease across the globe, it has led to an increase in the demand to manage asthma and chronic obstructive pulmonary disease which in turn is driving the growth of the short-acting beta-agonists market.
Short-Acting Beta-Agonists Market: Drivers and Restraints-
Increasing prevalence of asthma and chronic diseases such as chronic obstructive pulmonary diseases are driving the growth of the short-acting beta-agonists market.
The emergence of various drugs to treat severe asthma and novel combination therapies are expected to surge the growth of the short-acting beta-agonists market.
Furthermore, advancements in the technologies and also product innovation are leading to increased demand for short-acting beta-agonists. However, the exclusivity of branded drugs and expiry of patents are restricting the growth of the short-acting beta-agonists market.
Short-Acting Beta-Agonists Market: Overview
Based on the dosage form, solution and injectable are the most widely used dosage form in the short-acting beta-agonists market. Based on the application, short-acting beta-agonists are mainly used in the treatment of asthma due to the increasing demand to manage severe asthma attacks.
Based on the distribution channel, hospital pharmacies are the most profitable segment in the short-acting beta-agonists market.
Short-acting beta-agonists are the choice of drug in the market for treating asthma. They usually show their result within a few minutes to treat the symptoms such as wheezing, chest tightness, and shortness of breathing.
Commonly prescribed short-acting beta-agonists are albuterol, pirbuterol, levalbuterol. Apart from this, short-acting beta-agonists have several side effects such as headaches, suddenly noticeable heartbeats, trembling in the hands, muscle cramps, and others.
Scientists are continuously working to reduce the side effects of short-acting beta-agonists in treating asthma.
Short-Acting Beta-Agonists Market: Region-wise Outlook
North America and Europe are expected to dominate the global short-acting beta-agonists market, owing to the higher adoption of drugs and advancement in drug discovery in the regions.
Also, high prevalence rate of asthma and chronic obstructive pulmonary disease are expected to increase the growth of the short-acting beta-agonists market in these regions.
Increase in healthcare expenditure in the developing region like Asia-Pacific is expected to push the global short-acting beta-agonists market growth over the forecast period.
Also, rising population in countries like India and China is expected to further drive the growth of the market in these regions. In Middle East and Africa, the short-acting beta-agonist market is estimated to expand due to increasing asthma patients and increasing air pollution.
Short-Acting Beta-Agonists Market: Key Market Participants
Some of the market participants in the global short-acting beta-agonists market identified across the value chain include:
- Bayer AG
- Teva Pharmaceuticals Industries Ltd.
- F. Hoffmann-La Roche AG
- Mylan N.V.
- GlaxoSmithKline plc.
- Cipla Limited
- GlaxoSmithKline plc.
- Merck & Co.
- Schering-Plough Corporation
- Johnson & Johnson
The report covers exhaust analysis on:
- Short-acting beta-agonists Market Segments
- Short-acting beta-agonists Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain)
- Eastern Europe (Poland, Russia)
- Asia Pacific (India, ASEAN, Australia & New Zealand)
- Middle East and Africa (GCC Countries, S. Africa, Northern Africa)
- Detailed overview of parent market
- Changing market dynamics in the industry
- Short-acting beta-agonists -depth market segmentation
- Historical, current, and projected market size in terms of volume and value
- Short-acting beta-agonists recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Short-Acting Beta-Agonists Market: Segmentation
By dosage form:
- Chronic Obstructive Pulmonary Disease
By distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.